NCT07060001 2026-03-06
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT06802757 2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07317778 2026-01-05
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06451861 2025-11-17
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT06102824 2024-11-25
ORIENTA
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT00712881 2024-02-23
Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT02679040 2023-07-03
HIST-RIC
Institut Paoli-Calmettes
Phase 2 Unknown
NCT04499118 2020-08-05
AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer
Sichuan Provincial People's Hospital
Phase 2 Unknown
NCT00439920 2018-10-23
GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Unknown
NCT02084563 2016-11-08
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Hospital Israelita Albert Einstein
Phase 2 Completed